BackTransmedics Group Overview
Transmedics Group Inc

Transmedics Group Target Price

See Transmedics Group's analyst price targets ($100) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$91.38

Average Target Price

$100.259.7% upside

8 analysts in the last 4 months

High: $122 | Low: $65

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-11-06Canaccord GenuityJason Mills$12031.3% upsideOpen
2026-10-13Canaccord Genuity$942.9% upsideOpen
2026-10-06Barclays$12031.3% upsideOpen
2026-08-05Canaccord Genuity$954% upsideOpen
2026-08-05Robert W. Baird$12233.5% upsideOpen
2026-08-05Stifel Nicolaus$6528.9% downsideOpen
2026-08-03NeedhamMike Matson$10616% upsideOpen
2026-07-28UBS$8012.5% downsideOpen
2026-07-06Evercore ISIDaniel Markowitz$901.5% downsideOpen
2026-06-18Stifel Nicolaus$8012.5% downsideOpen
2026-05-26Stifel NicolausThomas Stephan$7517.9% downsideOpen
2026-05-06Canaccord GenuityWilliam Plovanic$12435.7% upsideOpen
2026-05-06Needham$14255.4% upsideOpen
2026-05-06Piper Sandler$12031.3% upsideOpen
2026-05-06Stifel NicolausThomas Stephan$857% downsideOpen
2026-05-06Robert W. BairdDavid Rescott$14053.2% upsideOpen
2026-03-09Stifel Nicolaus$13042.3% upsideOpen
2025-12-17Canaccord Genuity$14862% upsideOpen
2025-12-08Needham$16681.7% upsideOpen
2025-12-02Morgan Stanley$13547.7% upsideOpen
2025-10-30Piper SandlerMatt O'Brien$14053.2% upsideOpen
2025-10-30Canaccord GenuityJason Mills$14760.9% upsideOpen
2025-10-23Needham$14862% upsideOpen
2025-10-13Jefferies$14558.7% upsideOpen
2025-10-07Evercore ISI$15569.6% upsideOpen
2024-12-11Robert W. BairdDavid Rescott$12031.3% upsideOpen
2024-12-11Piper SandlerMatt O'Brien$901.5% downsideOpen
2024-10-29Robert W. BairdJoe Vruwink$15064.1% upsideOpen
2024-10-29Canaccord GenuityJason Mills$10919.3% upsideOpen
2024-10-29NeedhamMike Matson$10919.3% upsideOpen
2024-10-29OppenheimerSuraj Kalia$12536.8% upsideOpen
2024-09-23Robert W. BairdDavid Rescott$200118.9% upsideOpen
2024-09-04Piper SandlerMatt O'Brien$18097% upsideOpen
2024-08-21NeedhamMike Matson$208127.6% upsideOpen
2024-08-01Canaccord GenuityWilliam Plovanic$16984.9% upsideOpen
2024-08-01OppenheimerSuraj Kalia$200118.9% upsideOpen
2024-07-15Morgan StanleyPatrick Wood$14558.7% upsideOpen
2024-07-15Piper SandlerMatt O'Brien$17086% upsideOpen
2024-06-03StephensGeorge Sellers$15165.2% upsideOpen
2023-01-06Morgan Stanley$6331.1% downsideOpen
2022-08-03Morgan Stanley$3759.5% downsideOpen
2022-08-02Oppenheimer$4550.8% downsideOpen
2022-07-26Cowen & Co.$4550.8% downsideOpen
2022-06-29Morgan Stanley$3462.8% downsideOpen
2022-06-28Cowen & Co.$3957.3% downsideOpen
2022-05-04Morgan Stanley$2572.6% downsideOpen

Transmedics Group (TMDX) FAQ

Transmedics Group posts a target price of $100. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $100 for TMDX means covering analysts, on average, see the stock 9.7% upside of $91.38 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for TMDX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Transmedics Group's other metric pages and overview cover the third.

Judging Transmedics Group against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $100 here, then scan peer and history charts to see if the gap is persistent.